8-K: Callan JMB Reports 2025 Financials, Expands Logistics

Callan JMB Inc. announced its full year 2025 financial results, reporting a decrease in revenue and a significant increase in operating loss, while highlighting strategic growth initiatives in healthcare and emergency preparedness.

Summary

• Revenue for the twelve months ended December 31, 2025, was $5.7 million, a decrease from $6.6 million for the same period in 2024.
• Gross profit for 2025 was $2.1 million, down from $2.6 million in 2024.
• Selling, general and administrative (SG&A) expenses significantly increased to $8.6 million in 2025 from $4.8 million in 2024, primarily due to professional fees for the initial public offering and becoming a public entity, as well as increased information technology support costs.
• Loss from operations widened to $7.0 million in 2025, compared to a loss of $2.3 million in 2024.
• Net loss for 2025 was $7.97 million, compared to a net loss of $2.29 million in 2024.
• Cash and cash equivalents as of December 31, 2025, were $2.1 million, slightly up from $2.09 million in 2024.
• The company is actively pursuing growth initiatives in pharmaceutical logistics, specialty distribution, and U.S. onshoring.
• Key business highlights include new partnerships with Attune Biotech and Revival Health, expansion into India, and strengthening emergency preparedness contracts.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging financial report with substantial losses, offset by several promising strategic growth initiatives and new partnerships that could drive future revenue, but the immediate financial health is concerning.

Positives

• Deepened government relationships at both state and federal levels, particularly to support onshoring initiatives.
• Reinforced the strength and stability of core emergency preparedness operations.
• Signed a manufacturing oversight, federal deployment, and commercialization agreement with Biostax Corp d/b/a Attune Biotech Inc. for its multi-asset therapeutic pipeline.
• Established a joint venture with Revival Health to integrate logistics, shipping systems, bioservices, and data infrastructure.
• Launched Callan JMB Services (India) Private Limited with a planned temperature-controlled warehouse in Pune, Maharashtra, for pharmaceutical storage and distribution.
• Secured an agreement with Walkers Pharmaceuticals Ltd. and is working with additional Indian companies to facilitate U.S. market entry and manufacturing plant establishment.
• Entered a preliminary agreement with the maker of an oral drug delivery system to install innovative manufacturing equipment in its cGMP facility in Texas.
• Extended the emergency preparedness contract with the City of Chicago through June 2026 with a $1.5 million funding increase, bringing the total contract value to $9.1 million.
• Awarded a second five-year contract by the Oregon Health Authority (OHA) for medical emergency preparedness and response services.
• Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs.
• Supported Texas and New Mexico in response to measles outbreaks by redistributing MMR II vaccine doses from Chicago.
• Announced a new comprehensive lease program for vaccine management for government agencies and private organizations.
• Successfully administered immunizations across 44 Tennessee counties through a partnership with Health Hero Tennessee.
• Entered the food sampling sector by expanding reclamation operations.
• Upgraded the proprietary Sentry Monitoring System, transitioning from Java to HTML5 for enhanced accessibility and monitoring capabilities.

Negatives

• Revenue decreased by approximately 13% year-over-year, from $6.6 million in 2024 to $5.7 million in 2025, primarily due to decreased demand for emergency preparedness services by certain states and local governments.
• Gross profit decreased by approximately 18% year-over-year, from $2.6 million in 2024 to $2.1 million in 2025.
• SG&A expenses increased by nearly 78% year-over-year, from $4.8 million in 2024 to $8.6 million in 2025, largely due to IPO-related professional fees and IT support costs.
• Loss from operations widened significantly to $7.0 million in 2025, compared to a loss of $2.3 million in 2024.
• Net loss more than tripled, increasing to $7.97 million in 2025 from $2.29 million in 2024.
• Net loss per common share increased to $(1.82) in 2025 from $(0.87) in 2024.
• Cash flows from operating activities turned negative, resulting in a cash outflow of $(4,546,724) in 2025, compared to a cash inflow of $540,353 in 2024.
• An impairment loss on property and equipment of $542,088 was recognized in 2025.
• ELOC facility transaction expenses of $569,552 and changes in fair value of derivative liability of $371,216 contributed to the increased losses.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements.
• Additional risks and uncertainties that could impact forward-looking statements are discussed under 'Risk Factors' in the Company's Registration Statement Under the Securities Act of 1933 on Form S-1.

Future Outlook

The company is focused on strengthening its core infrastructure, scaling readiness capabilities, and advancing strategic growth initiatives in high-velocity sectors such as healthcare and food logistics throughout the remainder of 2026. It is committed to long-term shareholder value creation by building a resilient, mission-driven organization positioned at the center of critical healthcare and national preparedness supply chains.

Management Comments

• "Throughout 2025 and into the new year, while our emergency preparedness business has remained the core to our operations there are several critical initiatives Callan JMB is actively pursuing with significant growth potential."
• "Our long history and established relationships across both the state and federal levels continue to be a driver for us as potential partners seek out our knowledge and expertise."
• "While we are focused on maintaining exceptional service levels in emergency preparedness, we are also expanding our pharmaceutical logistics and specialty distribution operations, as well as advancing U.S. onshoring initiatives."
• "Callan JMB operates at the rigorous quality standards required for pharmaceutical distribution and our recent partnership with Attune represents a meaningful acknowledgement of our leadership in this space."
• "As we look ahead into the remainder of 2026, we are focused on strengthening our core infrastructure, scaling our readiness capabilities, and advancing our strategic growth initiatives in high velocity sectors such as healthcare and food logistics."
• "We are committed to long-term shareholder value creation by building a resilient, mission-driven organization positioned at the center of critical healthcare and national preparedness supply chains."

Industry Context

StockSavvy.ai notes that Callan JMB's strategic pivot towards pharmaceutical logistics, specialty distribution, and U.S. onshoring initiatives aligns with broader industry trends emphasizing supply chain resilience and domestic manufacturing, particularly in critical sectors like healthcare. The expansion into India also reflects a globalized approach to supply chain management, while the core emergency preparedness business remains a stable, albeit fluctuating, revenue stream.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Related party loans decreased from $18,669 in 2024 to $0 in 2025.
• Related party receivable of $3,300 in 2024.

Stakeholder Impact

• Shareholders: Significant net loss and increased operating expenses could negatively impact shareholder value in the short term, but strategic growth initiatives aim for long-term value creation.
• Customers (Healthcare Industry & Emergency Management Agencies): Continued focus on exceptional service levels, expanded offerings in pharmaceutical logistics, and strengthened emergency preparedness contracts suggest improved and diversified service capabilities.
• Employees: Expansion into new markets (e.g., India) and growth initiatives may lead to new opportunities, but financial losses could raise concerns.
• Creditors: Increased losses and negative operating cash flow could be a concern, though cash and cash equivalents remain stable.

Next Steps

• Strengthening core infrastructure.
• Scaling readiness capabilities.
• Advancing strategic growth initiatives in high velocity sectors such as healthcare and food logistics.
• Building a resilient, mission-driven organization positioned at the center of critical healthcare and national preparedness supply chains.
• Further developing Callan JMB Services (India) Private Limited and its planned temperature-controlled warehouse.
• Working with additional Indian companies to facilitate U.S. market entry and manufacturing plant establishment.
• Installing innovative manufacturing equipment from an oral drug delivery system maker in its Texas cGMP facility.

Key Dates

Recommendation

While the financial results for 2025 show a significant deterioration in profitability and cash flow from operations, the company is actively pursuing several strategic growth initiatives and partnerships in high-growth sectors like pharmaceutical logistics and onshoring. These initiatives, if successful, could turn the company's fortunes around. However, the current financial performance warrants caution, suggesting a 'hold' position to observe the execution and impact of these strategic shifts before making further investment decisions.

Keywords

logistics, healthcare logistics, cold chain logistics, emergency preparedness, pharmaceutical distribution, supply chain, onshoring, government contracts, biotech, food logistics, NASDAQ: CJMB, financial results, 2025 earnings